Work

A Phase 2b randomized clinical trial of the oral p38α inhibitor neflamapimod in dementia with Lewy bodies (DLB)

Year: 2026

Type: preprint

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Research Square

DOI: 10.21203/rs.3.rs-10623740/v1

Authors: John-Paul Taylor, John J. Alam, Stephen N. Gomperts, Lawrence S. Honig, Niels D. Prins, Isamil Koubiyr, Hui-May Chu, Amanda Gardner, Kelly Blackburn, Menno M. Schoonheim, Charlotte E. Teunissen, James E. Galvin

Institutions: Newcastle University, Massachusetts General Hospital, Columbia University, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, University of Miami

Language: English

Topic: Parkinson's Disease Mechanisms and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute on Aging

OpenAlex ID: W7203449997

Cites:

Cited by: 1

Related to: